ESTRO 2023 - Abstract Book

S1971

Digital Posters

ESTRO 2023

OS according to pathological stage was 3 years in T1, 5 years in T2, less than 2 years in T3 and less than 1 year in T1 stages.

There were statistically significant differences in terms of OS in favor of T1-T2 stages (p=0.061).

At 3 months, complete response (CR) was observed in 77% cases, stable lesion (SL) in 13%, progression (PG) in 7% a partial response (PR) in 3%.

At 6 months, CR was observed in 77% cases, SL in 8%, PG in 12% a PR in 3%.

At 12 months, CR was observed in 67% cases, SL in 13%, PG in 13% a PR in 7%.

Recurrences were observed in 14%, and all of them were treated, 50% with RT and 50% with surgery.

Progression free survival was 81% at 2 years and 69% at 5 years with no differences according to tumor stage (p=0.12). As October/22, 61% of patients are alive without skin lesion, 14% alive with skin lesion and 25% have died.

The cause of death was unrelated to the skin tumor in 89%.

Conclusion HDR plesiotherapy is a treatment option for non-melanoma skin cancer in fragile patients due to comorbidity or to avoid aesthetic impact due to scars with good results in local control and toxicity.

PO-2189 Plesiotherapy with 3D-printed custom molds for extramamary testicular Paget´s disease (EMPD)

C. F. Pedrero 1 , S. Guardado Gonzalez 1 , S. Fernandez Alonso 1 , C. Arias Guillén 1 , E. Capón Sáez 1 , G. Pozo Rodríguez 2 , A. Ferrando Sanchez 2 , J.F. Pérez-Regadera Gómez 1